Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Riding The Next Wave Of Biosimilars: Sandoz To Link Up With India's Biocon

Executive Summary

Pooling resources appears key to a major new collaboration in the biosimilars space, between Sandoz and India's Biocon, to develop the next generation of biosimilar immunology and oncology products.

Advertisement

Related Content

Mylan Pursues ‘Market First’ Playbook, Partners Lupin For Enbrel Biosimilar
Mylan Pursues ‘Market First’ Playbook, Partners Lupin For Enbrel Biosimilar
Biopharma Quarterly Dealmaking Statistics, Q1 2018
Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
Weak Q3 For Biocon, All Eyes On Biosimilars Approval Flow
Pharma Q4 Results Preview: J&J, Novartis, Celgene, Biogen & AbbVie
Keeping Track: Biosimilar Submissions Galore (And An Approval), Bayer Gets An Oncology Approval, KemPharm Resubmits Apadaz NDA
Mylan inks deal with Biocon for insulin analogs but preps for more in India?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100221

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel